Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REEM H GHALIB

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1558337782
CMS profile
25140
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$21.29

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $21.29 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie, Inc. $21.29 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REEM H GHALIB

NPI 1558337782 · CMS profile ID 25140

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558337782?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558337782?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558337782?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1558337782?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $21.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $21.2906/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647827065 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21.29 1
PY2020 $20.65 1
PY2021 $46.95 3
PY2024 $1,495.98 14
PY2025 $3,750.18 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,955.82 118
PY2024 Principal investigator $109,074.86 23
PY2023 Principal investigator $199,670.85 30
PY2022 Principal investigator $179,855.97 19
PY2021 Principal investigator $397,738.75 463
PY2020 Principal investigator $682,337.38 146
PY2019 Principal investigator $775,822.80 163

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

163 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $51,911.04 12/31/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670124507
Principal investigator 1 Allergan Inc. $1,025.00 12/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670117225
Principal investigator 1 Novo Nordisk AS $3,010.50 12/19/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467387
Principal investigator 1 Gilead Sciences, Inc. $3,555.00 12/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676522421
Principal investigator 1 Gilead Sciences, Inc. $9,178.00 12/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522425
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,721.35 12/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702081347
Principal investigator 1 Intercept Pharmaceuticals, Inc. $11,651.19 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702080379
Principal investigator 1 Novo Nordisk AS $2,013.30 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467375
Principal investigator 1 Novo Nordisk AS $2,700.00 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467377
Principal investigator 1 Novo Nordisk AS $1,562.00 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467379
Principal investigator 1 Novo Nordisk AS $11,000.00 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467381
Principal investigator 1 Novo Nordisk AS $12,000.00 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467383
Principal investigator 1 Novo Nordisk AS $1,200.00 12/03/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467385
Principal investigator 1 AbbVie, Inc. $732.80 11/27/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608383
Principal investigator 1 Gilead Sciences, Inc. $3,799.00 11/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676522409
Principal investigator 1 Gilead Sciences, Inc. $3,885.00 11/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522413
Principal investigator 1 Gilead Sciences, Inc. $34,379.00 11/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522417
Principal investigator 1 Gilead Sciences, Inc. $9,022.00 11/13/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522403
Principal investigator 1 Genentech, Inc. $6,206.37 11/07/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681097027
Principal investigator 1 Genentech, Inc. $7,197.84 11/07/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681108169
Principal investigator 1 Novo Nordisk AS $19.60 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713909
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713911
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713913
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713915
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713917
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713919
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713921
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713923
Principal investigator 1 Novo Nordisk AS $120.00 11/06/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713925
Principal investigator 1 Gilead Sciences, Inc. $27,120.00 11/04/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522399
Principal investigator 1 Novartis Pharmaceuticals Corporation $172.12 11/01/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO No dispute reported 06/30/2026 640727699
Principal investigator 1 AbbVie, Inc. $2,931.20 10/30/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608381
Principal investigator 1 Novo Nordisk AS $2,641.50 10/29/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467369
Principal investigator 1 Intercept Pharmaceuticals, Inc. $7,043.34 10/24/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702079225
Principal investigator 1 Gilead Sciences, Inc. $1,530.00 10/23/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 676396391
Principal investigator 1 Gilead Sciences, Inc. $1,710.00 10/23/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676522381
Principal investigator 1 Gilead Sciences, Inc. $5,383.00 10/23/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522388
Principal investigator 1 Gilead Sciences, Inc. $12,800.00 10/23/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522393
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,889.60 10/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702078401
Principal investigator 1 Genentech, Inc. $13,782.74 10/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681101445
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,484.85 10/10/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702077977
Principal investigator 1 Genentech, Inc. $48,338.59 10/01/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681102525
Principal investigator 1 Genentech, Inc. $2,091.00 10/01/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681117893
Principal investigator 1 AbbVie, Inc. $366.40 09/27/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608379
Principal investigator 1 Novo Nordisk AS $10,074.60 09/24/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467373
Principal investigator 1 Gilead Sciences, Inc. $3,120.00 09/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396383
Principal investigator 1 Gilead Sciences, Inc. $848.00 09/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis No dispute reported 06/30/2026 676522375
Principal investigator 1 Gilead Sciences, Inc. $2,329.00 09/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522379
Principal investigator 1 Gilead Sciences, Inc. $1,314.00 09/16/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 676396377
Principal investigator 1 Novo Nordisk AS $5.30 09/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713905
Principal investigator 1 Novo Nordisk AS $6.50 09/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713907
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 09/09/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522369
Principal investigator 1 AbbVie, Inc. $732.80 08/30/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608377
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,881.36 08/27/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702076171
Principal investigator 1 Gilead Sciences, Inc. $581.00 08/26/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522367
Principal investigator 1 Celgene Corporation $66.88 08/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis (CC-90001-NASH-001) No dispute reported 06/30/2026 675419059
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,471.85 08/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702075623
Principal investigator 1 Gilead Sciences, Inc. $12,366.00 08/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396371
Principal investigator 1 Gilead Sciences, Inc. $1,168.00 08/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis No dispute reported 06/30/2026 676522343
Principal investigator 1 Gilead Sciences, Inc. $2,445.00 08/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522349
Principal investigator 1 Gilead Sciences, Inc. $3,510.00 08/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522353
Principal investigator 1 Gilead Sciences, Inc. $5,295.00 08/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522359
Principal investigator 1 Novo Nordisk AS $9.80 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713891
Principal investigator 1 Novo Nordisk AS $60.00 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713893
Principal investigator 1 Novo Nordisk AS $9.98 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713895
Principal investigator 1 Novo Nordisk AS $36.00 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713897
Principal investigator 1 Novo Nordisk AS $5.30 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713899
Principal investigator 1 Novo Nordisk AS $25.98 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713901
Principal investigator 1 Novo Nordisk AS $6.50 08/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713903
Principal investigator 1 Novo Nordisk AS $9.80 08/13/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713875
Principal investigator 1 Novo Nordisk AS $60.00 08/13/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713877
Principal investigator 1 Novo Nordisk AS $11.38 08/13/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713879
Principal investigator 1 Novo Nordisk AS $9.98 08/13/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713881
Principal investigator 1 Novo Nordisk AS $36.00 08/13/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713883
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 08/12/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522335
Principal investigator 1 Novo Nordisk AS $5.30 08/09/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713885
Principal investigator 1 Novo Nordisk AS $25.98 08/09/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713887
Principal investigator 1 Novo Nordisk AS $6.50 08/09/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713889
Principal investigator 1 Genentech, Inc. $58,031.42 08/01/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681095777
Principal investigator 1 Novo Nordisk AS $2,000.00 07/30/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
NN9931-4492 No dispute reported 06/30/2026 692467371
Principal investigator 1 AbbVie, Inc. $366.40 07/29/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608375
Principal investigator 1 Intercept Pharmaceuticals, Inc. $7,783.96 07/25/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702074835
Principal investigator 1 Novo Nordisk AS $3.00 07/24/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713871
Principal investigator 1 Novo Nordisk AS $3.00 07/24/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713873
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 07/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676522327
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 07/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396365
Principal investigator 1 Gilead Sciences, Inc. $26.00 07/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676522319
Principal investigator 1 Gilead Sciences, Inc. $9,625.00 07/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522323
Principal investigator 1 Genentech, Inc. $2,316.56 07/02/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681071903
Principal investigator 1 AbbVie, Inc. $1,832.00 06/27/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608369
Principal investigator 1 Novo Nordisk AS $75.00 06/26/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713869
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 06/19/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396361
Principal investigator 1 Gilead Sciences, Inc. $3,765.00 06/19/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522309
Principal investigator 1 Gilead Sciences, Inc. $19,973.00 06/19/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522315
Principal investigator 1 Intercept Pharmaceuticals, Inc. $845.00 06/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702072747
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,757.34 06/18/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702072751
Principal investigator 1 Novo Nordisk AS $3.05 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713849
Principal investigator 1 Novo Nordisk AS $1.89 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713851
Principal investigator 1 Novo Nordisk AS $11.38 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713853
Principal investigator 1 Novo Nordisk AS $5.30 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713855
Principal investigator 1 Novo Nordisk AS $25.98 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713857
Principal investigator 1 Novo Nordisk AS $9.80 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713859
Principal investigator 1 Novo Nordisk AS $60.00 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713861
Principal investigator 1 Novo Nordisk AS $6.50 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713863
Principal investigator 1 Novo Nordisk AS $9.98 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713865
Principal investigator 1 Novo Nordisk AS $36.00 06/11/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713867
Principal investigator 1 AbbVie, Inc. $2,564.80 05/29/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608355
Principal investigator 1 Novo Nordisk AS $117.79 05/24/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 706713847
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,408.80 05/23/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702071283
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,664.00 05/23/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702071287
Principal investigator 1 AbbVie, Inc. $1,309.00 05/22/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608345
Principal investigator 1 AbbVie, Inc. $954.00 05/22/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608347
Principal investigator 1 AbbVie, Inc. $654.00 05/22/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608349
Principal investigator 1 AbbVie, Inc. $377.00 05/22/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608351
Principal investigator 1 AbbVie, Inc. $1,301.00 05/22/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608353
Principal investigator 1 Gilead Sciences, Inc. $873.00 05/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396351
Principal investigator 1 Gilead Sciences, Inc. $1,896.00 05/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 676396355
Principal investigator 1 Gilead Sciences, Inc. $999.00 05/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis No dispute reported 06/30/2026 676522295
Principal investigator 1 Gilead Sciences, Inc. $7,800.00 05/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522299
Principal investigator 1 Gilead Sciences, Inc. $16,009.00 05/22/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522305
Principal investigator 1 AbbVie, Inc. $854.00 05/21/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608343
Principal investigator 1 Genentech, Inc. $13,909.55 05/01/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681084491
Principal investigator 1 AbbVie, Inc. $1,832.00 04/29/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608339
Principal investigator 1 Gilead Sciences, Inc. $1,746.00 04/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396345
Principal investigator 1 Gilead Sciences, Inc. $4,628.00 04/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522285
Principal investigator 1 Gilead Sciences, Inc. $11,449.00 04/17/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522289
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,921.90 04/15/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702069731
Principal investigator 1 Intercept Pharmaceuticals, Inc. $8,842.80 04/04/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702068801
Principal investigator 1 Intercept Pharmaceuticals, Inc. $7,782.10 03/26/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702068207
Principal investigator 1 Intercept Pharmaceuticals, Inc. $14,884.70 03/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1010016 No dispute reported 06/30/2026 702067701
Principal investigator 1 Gilead Sciences, Inc. $8,358.00 03/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396339
Principal investigator 1 Gilead Sciences, Inc. $2,600.00 03/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis No dispute reported 06/30/2026 676522265
Principal investigator 1 Gilead Sciences, Inc. $4,662.00 03/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522271
Principal investigator 1 Gilead Sciences, Inc. $14,766.00 03/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522275
Principal investigator 1 Gilead Sciences, Inc. $16,530.00 03/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522279
Principal investigator 1 AbbVie, Inc. $732.80 02/28/2019 Non-covered Recipient Entity
Texas Clinical Research Institute
M13-576 No dispute reported 06/30/2026 647608309
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,152.78 02/26/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1009742 No dispute reported 06/30/2026 702066611
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,395.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066147
Principal investigator 1 Intercept Pharmaceuticals, Inc. $400.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066151
Principal investigator 1 Intercept Pharmaceuticals, Inc. $450.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066157
Principal investigator 1 Intercept Pharmaceuticals, Inc. $570.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066163
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,450.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066171
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,475.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066175
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,700.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066181
Principal investigator 1 Intercept Pharmaceuticals, Inc. $10,400.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066187
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,085.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066193
Principal investigator 1 Intercept Pharmaceuticals, Inc. $200.00 02/21/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
1011866 No dispute reported 06/30/2026 702066199
Principal investigator 1 Gilead Sciences, Inc. $1,746.00 02/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676396333
Principal investigator 1 Gilead Sciences, Inc. $1,108.00 02/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis No dispute reported 06/30/2026 676522247
Principal investigator 1 Gilead Sciences, Inc. $1,155.00 02/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522251
Principal investigator 1 Gilead Sciences, Inc. $1,895.00 02/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522257
Principal investigator 1 Gilead Sciences, Inc. $11,568.00 02/20/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522262
Principal investigator 1 Genentech, Inc. $18,819.00 02/19/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681085565
Principal investigator 1 Genentech, Inc. $12,546.85 02/12/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681080813
Principal investigator 1 Genentech, Inc. $2,281.25 02/12/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681084489
Principal investigator 1 Genentech, Inc. $2,500.00 02/12/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681084543
Principal investigator 1 Genentech, Inc. $4,795.00 02/12/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681092077
Principal investigator 1 Genentech, Inc. $18,485.00 02/12/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A PHASE IB RANDOMIZED BLINDED PLACEBO CONTROLLED MULTIPLE ASCENDING DOSE STUDY WITH BFKB8488A No dispute reported 06/30/2026 681093449
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,258.00 02/04/2019 Non-covered Recipient Entity
Texas Clinical Research Institute, Llc
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND COMPENSATED LIVER CIRRHOSIS No dispute reported 06/30/2026 639761501
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,646.00 02/04/2019 Non-covered Recipient Entity
Texas Clinical Research Institute, Llc
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND STAGE 3 LIVER FIBROSIS No dispute reported 06/30/2026 639761503
Principal investigator 1 Gilead Sciences, Inc. $2,968.00 01/28/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522229
Principal investigator 1 Gilead Sciences, Inc. $4,620.00 01/28/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676522235
Principal investigator 1 Gilead Sciences, Inc. $10,860.00 01/28/2019 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study evaluating the safety and efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in subjects with bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676522239